Please check your internet connection and try again.
# Hyaluronic Acid
## Overview
Hyaluronic acid (HA) is a naturally occurring high-molecular-weight glycosaminoglycan found in connective tissue, synovial fluid, and the extracellular matrix. Exogenous HA is utilized for its viscoelastic, lubricating, and hygroscopic properties.
## Primary Indications
* **Osteoarthritis (OA):** Symptomatic management of knee osteoarthritis in patients failing conservative therapy.
* **Ophthalmology:** Surgical aid in ocular procedures (e.g., cataract extraction) or dry eye management (topical).
* **Dermatology:** Dermal fillers for contour correction or topical agents for hydration.
## Adult Dosing
* **Intra-articular (Knee OA):** Dosing varies significantly by product formulation (e.g., Hyalgan, Synvisc, Euflexxa).
* *Standard (e.g., Hyalgan):* 20 mg (2 mL) injected intra-articularly once weekly for 3–5 weeks.
* *Single-Dose (e.g., Synvisc-One):* 48 mg (6 mL) injected once into the knee joint.
* *Note:* Strictly follow the specific product package insert; products are not interchangeable.
* **Ocular (Dry Eye):** 0.1%–0.3% solution administered 1–4 times daily as needed.
## Pediatric Dosing
Safety and efficacy have not been established for intra-articular use in pediatric patients. Use is generally restricted to topical ophthalmic drops if clinically indicated by an ophthalmologist.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No adjustments required as systemic absorption is negligible for intra-articular injections.
* **Elderly:** Use caution in patients with severe inflammatory joint disease or active infection.
## Contraindications
* Known hypersensitivity to hyaluronan preparations.
* Active joint infection, skin disease, or infection in the area of the injection site.
* Known hypersensitivity to avian proteins (if the product is derived from rooster combs—e.g., Hyalgan, Synvisc).
## Adverse Effects
* **Injection Site:** Transient pain, swelling, erythema, joint effusion, and warmth.
* **Systemic (Rare):** Pseudoseptic reaction (acute inflammatory response within 24–48 hours of injection), hypersensitivity/anaphylactoid reactions.
* **Ocular:** Blurred vision or mild stinging upon topical application.
## Key Drug Interactions
No clinically significant systemic drug-drug interactions are established due to the site-specific nature of intra-articular HA. Avoid concurrent intra-articular injections of quaternary ammonium salts (e.g., benzalkonium chloride) as they may cause HA to precipitate.
## Monitoring
* Monitor for signs of increased inflammation or joint effusion post-injection.
* Monitor for systemic hypersensitivity reactions within the first few hours post-administration.
## Clinical Pearls
* **Not a Cure:** HA is considered a viscosupplement; it provides pain relief by lubricating the joint and potentially inhibiting inflammatory mediators, but it does not reverse joint degradation.
* **Delayed Onset:** Clinical improvement may not be noted for several weeks post-injection.
* **Aseptic Technique:** Strict sterile technique is mandatory for intra-articular injections to prevent iatrogenic septic arthritis.
* **Source Sensitivity:** Verify if the product is avian-derived (rooster comb) or bio-fermented if the patient reports a history of poultry allergies.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and product-specific prescribing information can change. Always verify current FDA-approved labeling, institutional protocols, and specific product inserts before prescribing or administering medication.
